HCA Healthcare (NYSE:HCA) Posts Earnings Results

HCA Healthcare (NYSE:HCA) released its quarterly earnings data on Friday. The company reported $6.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.03 by $0.19, RTT News reports. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same period in the previous year, the firm posted $5.90 EPS. HCA Healthcare updated its FY 2025 guidance to 24.050-25.850 EPS.

HCA Healthcare Price Performance

Shares of HCA opened at $320.24 on Friday. The firm has a market capitalization of $81.12 billion, a PE ratio of 14.37, a price-to-earnings-growth ratio of 1.09 and a beta of 1.64. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. HCA Healthcare has a 1-year low of $279.93 and a 1-year high of $417.14. The company’s fifty day moving average price is $314.50 and its 200-day moving average price is $352.84.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $380.00 target price on shares of HCA Healthcare in a report on Tuesday, December 17th. Oppenheimer raised their price objective on HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a research report on Monday, October 28th. TD Cowen cut their price objective on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a research report on Monday, October 28th. Morgan Stanley dropped their price target on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $392.00 price target on shares of HCA Healthcare in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $385.27.

Insider Activity

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the transaction, the insider now owns 6,843 shares in the company, valued at approximately $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Phillip G. Billington sold 3,897 shares of the company’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the transaction, the senior vice president now owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. This trade represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.